Canagliflozin

Verdict: Probable (in male mice) / Probable (in CKD/CV/diabetes populations on hard endpoints) / Suggestive (general aging in non-diabetic, non-CKD adults) Last reviewed: 2026-04-25 Triangulated against anchor: Rapamycin (Probable)

TL;DR

Canagliflozin extended male mouse lifespan by 14% (ITP, late-life initiation), with no effect or slight harm in females. Independently, SGLT2 inhibitors as a class have produced large hard-endpoint reductions in cardiovascular and renal outcomes in humans (CANVAS, CREDENCE, EMPA-REG, DAPA-HF, EMPEROR — across the SGLT2 class). The aging case is unusually strong: positive ITP signal plus large human RCT evidence in adjacent indications. Probable in male mice; Probable in CV/renal/diabetes populations on hard endpoints; Suggestive in general aging contexts.

What it is

A sodium-glucose cotransporter 2 (SGLT2) inhibitor. Reduces renal glucose reabsorption → glycosuria → modest weight loss + glucose lowering + osmotic effects on plasma volume. Approved for T2DM, CKD, and HFrEF/HFpEF. Class includes empagliflozin, dapagliflozin, ertugliflozin. Typical dose: 100-300 mg/day.

Proposed mechanism

• Glucosuria → caloric loss + reduced postprandial glucose excursions → CR-like signaling
• Reduced cardiac preload via osmotic diuresis
• Cardiac and renal protective effects beyond glucose lowering — likely involving ketone metabolism, sodium/hydrogen exchange, sympathetic modulation
• Possible direct anti-fibrotic and senescence-modulating effects (active research area)

Confidence: Established for the diabetes / CV / renal mechanisms; Plausible for the broader aging mechanism.

Evidence ladder

Animal models (T3 — sex-specific)

• ITP (Miller 2020 / 2024): canagliflozin started at 6 months extended male median lifespan ~14% with no female effect; later cohorts confirmed.
• Late-life initiation (16 months): +14% males, ~6% decline in females — the female harm signal is concerning and worth flagging.
• Mechanism in rodents — engages mTOR / MAPK signaling overlapping with rapamycin's pathway; this is mechanistically informative.

Human (T1 — for adjacent indications)

The unusual feature of canagliflozin's evidence base: SGLT2 inhibitors have T1 hard-endpoint evidence in multiple large RCTs for indications adjacent to longevity:

• CANVAS (Neal 2017 NEJM) — canagliflozin in T2DM with CV risk: reduced MACE.
• CREDENCE (Perkovic 2019 NEJM) — canagliflozin in diabetic kidney disease: reduced kidney failure and CV death.
• EMPA-REG (empagliflozin), DAPA-HF (dapagliflozin), EMPEROR-Reduced/Preserved — class-wide CV and HF benefits, including in non-diabetic populations.
• All-cause mortality reductions are documented in pooled SGLT2-inhibitor analyses across indications.

The broader class evidence supports SGLT2 inhibition as having genuine hard-endpoint benefit in defined populations.

Aging-specific human trials

• No formal aging-endpoint RCT in non-diabetic non-CKD non-HF adults.
• Off-label longevity use exists in some clinics; protocols are extrapolated.

Confounds

• Sex bias parallels acarbose / 17α-estradiol — males respond, females may even be slightly harmed in late-life initiation. This is a real mechanistic puzzle and a flag for translation.
• Population specificity in human trials — all major positive RCTs are in T2DM, CKD, or HF populations. Generalizing to healthy adults requires inference.
• Side effects — genital mycotic infections (women particularly), DKA risk (rare but real), volume depletion at initiation.
• Amputation signal in early CANVAS data did not replicate in subsequent trials but warrants tracking.

Conflict of interest scan

• ITP work is NIA-funded; no discount.
• Major SGLT2 RCTs are pharmaceutical-funded but pre-registered, FDA-grade — minimal effective discount.
• Net: clean evidence base.

Human translation

Honest decomposition:

1. In T2DM / CKD / HF populations: SGLT2 inhibition (including canagliflozin) reduces hard endpoints including CV death and mortality. Probable verdict at the population level.
2. In non-diabetic, non-CKD adults: the trial evidence does not extend; class-effect extrapolation is plausible but not direct.
3. In male mice: ITP evidence is strong; female mouse data is concerning.
4. For longevity supplementation in healthy adults: Suggestive at best; the female-harm signal in late-life mice is an honesty caveat.

The key under-discussed point: canagliflozin and other SGLT2s have better hard-endpoint human evidence than rapamycin in their indicated populations. That raises the question of whether longevity-medicine clinics over-emphasize rapamycin and under-emphasize SGLT2s for the populations where they're already indicated.

Calibrated verdict

Population-stratified:

• Probable in T2DM/CKD/HF populations (T1 hard-endpoint evidence).
• Probable in male mice from ITP.
• Suggestive as a general aging intervention in healthy adults.
• Caveat: female late-life signal warrants caution.

Compared to rapamycin (Probable), canagliflozin has better hard-endpoint human evidence (in adjacent indications) and comparable male-specific mouse evidence; rapamycin has broader sex effects in mice and more longevity-specific human surrogate data.

Compared to GLP-1 agonists (Probable in obese/CV), both have T1 hard-endpoint human evidence in metabolic disease populations and are emerging "longevity therapeutics" by extrapolation.

Confidence interval on verdict

• Diabetes/CKD/HF verdicts: stable; possibly upgrade to Strong with continued follow-up.
• General aging verdict: could move to Probable if specifically tested in non-diabetic aging-endpoint trials.
• Most likely 2-year trajectory: stable; class evidence continues to consolidate.

Open questions

• Q: What is the mechanism of the female late-life harm signal in mice? Does it predict any female-specific human risk?
• Q: For non-diabetic adults at moderate CV risk, what is the marginal benefit of SGLT2 inhibition vs current standard of care?
• Q: How does the canagliflozin effect compare to empagliflozin / dapagliflozin in mouse aging models?
• Q: Are there ongoing or planned aging-endpoint trials of SGLT2 inhibitors in non-diabetic populations?

Sources

• Miller et al. 2020 — Canagliflozin extends life span in genetically heterogeneous male but not female mice (PMC7710304)
• bioRxiv 2020 — Canagliflozin extends lifespan in male mice
• Canagliflozin shares common mTOR/MAPK signaling mechanisms with other lifespan extension treatments
• Neal et al. 2017, NEJM — CANVAS canagliflozin and CV outcomes in T2DM
• Perkovic et al. 2019, NEJM — CREDENCE canagliflozin in diabetic kidney disease

Produced under methodology locked 2026-04-24. Triangulated against rapamycin anchor.